Bio-Path (NASDAQ:BPTH) Rating Lowered to Hold at ValuEngine

Bio-Path (NASDAQ:BPTH) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Tuesday, ValuEngine reports.

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 price objective (down previously from $28.00) on shares of Bio-Path in a report on Monday.

Shares of Bio-Path stock opened at $7.30 on Tuesday. Bio-Path has a 1 year low of $1.61 and a 1 year high of $73.52. The firm has a market cap of $21.02 million, a price-to-earnings ratio of -0.51 and a beta of 3.05. The company has a 50-day moving average of $10.22 and a 200 day moving average of $12.04. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.85 and a quick ratio of 13.85.

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Bio-Path by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock worth $374,000 after purchasing an additional 2,601 shares in the last quarter. BlackRock Inc. grew its stake in shares of Bio-Path by 17.5% in the 2nd quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock worth $628,000 after buying an additional 6,978 shares during the last quarter. Finally, Morgan Stanley increased its position in Bio-Path by 19,858.0% during the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after buying an additional 19,858 shares in the last quarter. 6.13% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Recommended Story: Candlestick

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.